The US FDA's approval of CSL's ANDEMBRY (garadacimab) for hereditary angioedema provides another opportunity to compare patient access to innovative treatments in the US and Australia. …
One CSL innovation that allows for a direct and timely comparison
June 18, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The Dispatched 'Week in Review' Podcast - 3 October
October 3, 2025 - - Podcast -
The challenge is for our gatekeepers. Can they see beyond the gate?
October 3, 2025 - - Latest News -
Trump administration links MFN and lower prices to faster FDA approvals
October 3, 2025 - - Latest News -
Vertex appoints Elisha Whitfield as senior country manager for Australia and New Zealand
October 2, 2025 - - Latest News -
Race Oncology uncovers novel anticancer mechanism for bisantrene
October 2, 2025 - - Australian Biotech -
Mark Butler announces boost for clinical trial reform, after years of delay
October 2, 2025 - - Latest News -
Pharmac moves to ease access to HIV medicines in New Zealand
October 2, 2025 - - Latest News